AbbVie’s Skyrizi Tops Novartis’s Cosentyx In Psoriasis Contest
Head-To-Head Result Will Fuel IL-23 Versus IL-17 Debate
A Phase III clinical trial comparing AbbVie's Skyrizi with Novartis's IL-17 agonist Cosentyx showed the former's superiority in adults with moderate-to-severe plaque psoriasis.
